Browsing Tag
MASH clinical trial
1 post
PRD Therapeutics begins first-in-human trial for PRD001 targeting HoFH and MASH
PRD Therapeutics initiates first-in-human clinical trial of PRD001, a novel SOAT2-selective inhibitor for HoFH and MASH, showing promise in preclinical models.